EXETER, N.H.--(BUSINESS WIRE)--Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company, today announced that its abstract entitled “Interim Results of a Randomized, Single-Dose, 4-Way Crossover, Pharmacokinetic Study of Intranasal Insulin Spray (Nasulin™), Injectable Regular Insulin (Humulin R®), Injectable Fast-Acting Insulin (Humalog®), and Saline Nasal Spray in Patients with Type I Diabetes Mellitus,” has been selected for oral presentation at the American Diabetes Association 67th Scientific Sessions in Chicago. Dr. Sherwyn L. Schwartz, M.D., of dgd Research, Inc., will make the presentation as part of the first session on Friday, June 22, 2007.
